Loading clinical trials...
Loading clinical trials...
A Randomized, Placebo-controlled, Double-blind, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Repeated Subcutaneous (SC) Doses of REMD-477 in Subjects With Type 2 Diabetes Mellitus
Conditions
Interventions
REMD-477
Locations
3
United States
Miami, Florida, United States
San Antonio, Texas, United States
Renton, Washington, United States
Start Date
September 1, 2015
Primary Completion Date
January 1, 2018
Completion Date
February 1, 2018
Last Updated
April 10, 2018
NCT05398783
NCT07224321
NCT01399385
NCT07395050
NCT06513026
NCT07340320
Lead Sponsor
REMD Biotherapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions